Ensure Compliance: Firms Making Poor Quality Drugs Must Face Consequences
The Union Health Ministry is pushing for strict drug compliance following reports of contaminated cough syrups. The Tamil Nadu Drugs Control Department found diethylene glycol (DEG) and ethylene glycol in samples of Coldrif, a cough syrup linked to child deaths in Rajasthan and Madhya Pradesh. These substances are nephrotoxic and highly dangerous. The Central Drugs Standard Control Organisation (CDSCO) has recommended cancelling the firm's manufacturing license. The article emphasizes the need for a zero-tolerance policy, hawk-like monitoring, and regular surprise inspections to uphold the 'Make in India' brand and protect public health from substandard pharmaceutical products.
Key Points
- Contaminated cough syrups containing DEG and ethylene glycol have been linked to multiple child deaths in India.
- The CDSCO has recommended the cancellation of manufacturing licenses for firms failing to meet quality standards.
- Revised Schedule M norms are being implemented to ensure Indian pharmaceutical products meet global Good Manufacturing Practices (GMP).
- A zero-threshold policy for poor quality drugs is essential to maintain the credibility of the Indian pharmaceutical sector.
Exam Facts
- Diethylene glycol (DEG) and ethylene glycol are nephrotoxic substances found in contaminated syrups.
- CDSCO is the national regulatory body for Indian pharmaceuticals.
- Revised Schedule M of the Drugs and Cosmetics Rules focuses on Good Manufacturing Practices (GMP).
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.